Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Operating Expenses (2019 - 2025)

Keros Therapeutics filings provide 7 years of Operating Expenses readings, the most recent being $29.7 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 47.32% to $29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $176.5 million, a 17.67% decrease, with the full-year FY2025 number at $176.5 million, down 17.67% from a year prior.
  • Operating Expenses hit $29.7 million in Q4 2025 for Keros Therapeutics, roughly flat from $29.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $59.2 million in Q1 2025 to a low of $15.6 million in Q2 2021.
  • Median Operating Expenses over the past 5 years was $35.4 million (2022), compared with a mean of $37.6 million.
  • Biggest five-year swings in Operating Expenses: soared 96.46% in 2022 and later plummeted 49.79% in 2025.
  • Keros Therapeutics' Operating Expenses stood at $24.9 million in 2021, then grew by 28.53% to $32.0 million in 2022, then surged by 45.8% to $46.6 million in 2023, then grew by 20.81% to $56.3 million in 2024, then crashed by 47.32% to $29.7 million in 2025.
  • The last three reported values for Operating Expenses were $29.7 million (Q4 2025), $29.6 million (Q3 2025), and $58.0 million (Q2 2025) per Business Quant data.